Anders Ternhag

Introduction

We are studying the use of antibiotics in the population in a broad sense. This is done mainly by various epidemiological register based studies.

But we are also responsible for two governmental funded national RCT:s. The first will examine clinical effect and the impact on gut microbiota of temocilline vs. cefotaxime for febrile UTI. The second will compare clinical effect of 10 days with PcV 1gx3 vs. 5 days with PcV 500 mg 1x4.

Finally, we have work on antibiotic resistance and more specifically on health economic consequences in a collaboration project with Gothenburg University.

Major research focus

Antibiotic use, pharmacoepidemiology, clinical effect, microbiota, adverse outcomes of URTIs

Team members

Anders Ternhag, MD, PhD, Associate Professor, Team Leader

Key Publications

A microsimulation model projecting the health care costs for resistance to antibacterial drugs in Sweden.
Larsson S, Prioux M, Fasth T, Ternhag A, Struwe J, Dohnhammar U, et al
Eur J Public Health 2018 Oct;():

A microsimulation model projecting the health care costs for resistance to antibacterial drugs in Sweden.
Larsson S, Prioux M, Fasth T, Ternhag A, Struwe J, Dohnhammar U, et al
Eur J Public Health 2018 Oct;():

A randomized controlled study of 5 and 10 days treatment with phenoxymethylpenicillin for pharyngotonsillitis caused by streptococcus group A - a protocol study.
Skoog G, Edlund C, Giske CG, Mölstad S, Norman C, Sundvall PD, et al
BMC Infect. Dis. 2016 09;16():484

Antibiotic consumption among a Swedish cohort of children born in 2006.
Hellman J, Grape M, Ternhag A
Acta Paediatr. 2015 Oct;104(10):1035-8

Antibiotic consumption in relation to socio-demographic factors, co-morbidity, and accessibility of primary health care.
Ternhag A, Grünewald M, Nauclér P, Wisell KT
Scand. J. Infect. Dis. 2014 Dec;46(12):888-96

More on U.S. outpatient antibiotic prescribing, 2010.
Ternhag A, Hellman J
N. Engl. J. Med. 2013 09;369(12):1175